NETTER-1 phase III study: 177Lu-dotatate in midgut NETs

Speaker: Jonathan Strosberg

J. Strosberg digs into results from first randomised study with radiolabelled somatostatin analogue peptides in patients with midgut neuroendocrine tumours (NETs). The primary endpoint of progression-free survival is longer at interim analysis with also favourable overall survival and response rate, the data to be confirmed in final analysis. Renal toxicity is tolerable; myelosuppression is in general mild, however, there is a concern of later myelodysplastic syndrome and leukaemia, currently predicted to be low.

Discussion Points

  1. Rationale for the study
  2. Key study findings
  3. Practice perspective

O-009: NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate. Jonathan Strosberg, et al.